Nathan Jibat

Health Policy Researcher at John Hopkins Bloomberg School of Public Health

[Nathan Jibat @NTolemariam]

Our analysis in @Health_Affairs explores how U.S. Most Favored Nation pricing proposals could reshape global pharmaceutical markets, highlighting the need to balance domestic affordability with international patient access.

[Health Affairs @Health_Affairs]

Repatha’s withdrawal from Denmark is best understood as an early signal of the impact of Most Favored Nation drug pricing proposals in the US. When low-price foreign markets become linked to large U.S. markets, access disruptions are a predictable risk. | Forefront

Nathan Jibat and @jeromie_b | @JohnsHopkins, @JohnsHopkinsSPH

https://t.co/zRXW6khzNj

[Nathan Jibat @NTolemariam]

@IssrafilA Tastes like that small እድፍ between your toes after wearing the same socks for months